Microalbuminuria as surrogate endpoint in therapeutic trials

Current Hypertension Reports

Volumn 14, Issue 4, 2012, Pages 345-349

  Redon, Josep ^a,b   Martinez, Fernando ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Albuminuria; Diabetes; High cardiovascular risk; Hypertension; Microalbuminuria; Surrogate endpoint

Indexed keywords

ALBUMIN; ATENOLOL; INDAPAMIDE; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CIRCADIAN RHYTHM; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MICROALBUMINURIA; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; URINARY EXCRETION;

ALBUMINS; ALBUMINURIA; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; PROGNOSIS; RISK FACTORS;

EID: 84865643317     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-012-0270-y     Document Type: Article

References (20)

1. Cohn JN. Introduction to Surrogate Markers. Circulation. 2004;1 (25 Suppl 1):IV20.
2. Fleming T, David D. Surrogate end points in clinical trials: Are we being misled? Ann Intern Med. 1996;125:605-13. (Pubitemid 126450094)
3. Food and Drug Administration, title 21 (2011). 5: 21CFR314.510.
4. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007;370:829-40. (Pubitemid 47362321)
5. Dahlöf B, Devereux RB, Kjeldsen SE, Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995-1003. (Pubitemid 34286536)
6. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59. (Pubitemid 351522739)
7. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensinconverting enzyme inhibitors: A randomised controlled trial. Lancet. 2008;372:1174-83.
8. Redon J, Pascual JM. Development of microalbuminuria in essential hypertension. Curr Hypertens Rep. 2006;8:171-7. (Pubitemid 43803132)
9. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Management of arterial hypertension of the European society of hypertension; European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-87. (Pubitemid 46924065)
10. Russo LM, Bakris GL, Comper WD. Renal handling of albumin: A critical review of basic concepts and perspective. Am J Kidney Dis. 2002;39:899-919. (Pubitemid 34460554)
11. Bigazzi R, Bianchi S. Microalbuminuria as a marker of cardiovascular and renal disease in essential hypertension. Nephrol Dial Transplant. 1995;10 suppl 6:10-4.
12. Redon J, Miralles A, Lurbe A, Pascual JM, Lozano JV. Urinary albumin excretion at night in essential hipertensión. Med Clin. 1995;104:608-11. in Spanish.
13. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-72. (Pubitemid 351831357)
14. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20:1813-21. The manuscript analyzed the changes in urinary albumin excretion and their relationship with cardiovascular and renal outcomes in type 2 diabetic subjects in the ADVANCE study. Changes in microalbuminuria were linked with cardiovascular events.
15. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care. 2006;29:595-600. (Pubitemid 44115360)
16. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45:198-202. (Pubitemid 40179960)
17. Olsen MH,Wachtell K, Ibsen H, Lindholm L, Kjeldsen SE, Omvik P, et al. Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: A LIFE substudy. J Hypertens. 2011;29:997-1004.
18. Schmieder RE, Mann JF, Schumacher H, Gao P, Mancia G, Weber MA, et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol. 2011;22:1353-64.
19. The manuscript analyzed the changes in urinary albumin excretion and their relationship with cardiovascular and renal outcomes in high risk subjects in the ONTARGET/TRASCEND study. Changes in microalbuminuria were linked with cardiovascular and renal events.
20. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-58. This reappraisal of the ESH-ESC guidelines reviewed the evidence published with the release of the Guidelines in 2007.